Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988163 | 0.96 | MAPT (0.38) | MAPTLMNAALDH1A1KDM4EGLA | |
| SCHEMBL988602 | 0.85 | ALDH1A1 (0.38) | MAPTLMNAALDH1A1KDM4EGLA | |
| SCHEMBL10209683 | 0.80 | LMNA (0.39) | MAPTLMNAALDH1A1KDM4ERAB9A | |
| SCHEMBL10209810 | 0.77 | LMNA (0.37) | MAPTLMNAALDH1A1KDM4ERAB9A | |
| SCHEMBL12440136 | 0.75 | GAA (0.40) | LMNAALDH1A1KDM4EMAPK1GAA | |
| SCHEMBL15180112 | 0.74 | LMNA (0.34) | MAPTLMNAALDH1A1KDM4ERAB9A | |
| SCHEMBL15180116 | 0.74 | TNKS2 (0.49) | MAPTLMNAALDH1A1KDM4EMAPK1 | |
| SCHEMBL431949 | 0.74 | MAPT (0.37) | MAPTLMNAALDH1A1KDM4ERAB9A | |
| SCHEMBL6580601 | 0.72 | ALDH1A1 (0.46) | MAPTLMNAALDH1A1KDM4ERAB9A | |
| SCHEMBL12438683 | 0.72 | KDM4E (0.53) | MAPTLMNAALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213664-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-8552016-B2 | Anti-cancer cyclopenta(g)quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-8486955-B2 | Anti-cancer cyclopenta [g] quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-8063056-B2 | Anti-cancer cyclopenta [g]quinazonline compounds | BTG INTERNATIONAL LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| EP-1420809-B1 | USE OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR TREATING CANCER | BTG INT LTD (GB) | 2011-09-28 | — | — | EP | disclosed |
| EP-1421069-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| EP-2332962-A1 | Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions | BTG International Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| EP-2311850-A1 | Anti-cancer cyclopenta[g]quinazoline compounds | BTG International Limited (GB) | 2011-04-20 | — | — | EP | disclosed |
| US-7863284-B2 | Anti-cancer cyclopenta[G]quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2011-01-04 | — | — | US | disclosed |
| US-20100273817-A1 | Anti-cancer cyclopenta(g)quinazoline compounds | BGT International Limited (GB) | 2010-10-28 | — | — | US | disclosed |
| US-7250511-B2 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-20050009851-A1 | Use of cyclopeta[g]quinazoline derivatives for treating cancer | BTG INTERNATIONAL LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| US-20040266798-A1 | Process for the preparation of cyclopenta[g]quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
| US-20040242606-A1 | Anti-cancer cyclopenta (g)quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1421105-A1 | ANTI-CANCER CYCLOPENTA[G]QUINAZOLINE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1420809-A1 | USE OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR TREATING CANCER | BTG International Limited (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1421069-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG International Limited (GB) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003020748-A1 | ANTI-CANCER CYCLOPENTA[G]QUINAZOLINE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020300-A1 | USE OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR TREATING CANCER | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020706-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[g]QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273817-A1 | Anti-cancer cyclopenta(g)quinazoline compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1, NR0B1 | MAPT 4843/4885LMNA 2890/4885ALDH1A1 1231/4885 |
| US-20040266798-A1 | Process for the preparation of cyclopenta[g]quinazoline derivatives | COX6A1, MT-ND6, CYP2D6 | MAPT 3724/4885LMNA 2171/4885ALDH1A1 1243/4885 |
| US-20040242606-A1 | Anti-cancer cyclopenta (g)quinazoline compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR4A1 | MAPT 4820/4885LMNA 1126/4885ALDH1A1 808/4885 |
| US-20050009851-A1 | Use of cyclopeta[g]quinazoline derivatives for treating cancer | CNR1, NR3C1, NR0B1 | MAPT 4847/4885LMNA 4377/4885ALDH1A1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.